- About Us
- Advertise
- Contact Us
- CureToday.com
- CancerNetwork.com
- OncLive.com
- Do Not Sell My Information
- Privacy
- Terms & Conditions
© 2021 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Breast Cancer | Clinical
Pembrolizumab Plus Chemotherapy Significantly Reduces the Risk of EFS Events in TNBC
July 16, 2021
The combination of the ant-PD-1 inhibitor, pembrolizumab plus chemotherapy before surgery continued by pembrolizumab as a single agent led to statistically significant event-free survival result versus neoadjuvant chemotherapy alone in patients with high-risk early-stage triple-negative breast cancer.
OS Improves With Addition of Ribociclib/Endocrine Therapy in Advanced Breast Cancer
July 08, 2021
Regardless of age the combination of ribociclib and endocrine therapy led to improved overall survival in pre- or postmenopausal patients with hormone receptor-positive, HER2-negative advanced breast cancer.
Promising Antitumor Activity for Datopotamab Deruxtecan in TNBC
July 06, 2021
Encouraging findings from theTROPION-PanTumor01 trial revealed a positive response and safety profile for the antibody-drug conjugate datopotamab deruxtecan in patients with triple-negative breast cancer.
Atezolizumab Plus Carboplatin Induces Early Efficacy Signals in Invasive Lobular Breast Cancer
July 06, 2021
Treatment with atezolizumab plus carboplatin demonstrated early clinical activity in patients with metastatic invasive lobular breast cancer, with slight trends toward increased clinical benefit in patients with triple-negative ILC and responders with higher PD-L1 expression.
Potential Role for Amcenestrant in the Treatment of ER+/HER2- Advanced Breast Cancer
June 30, 2021
Sara Hurvitz, MD, provides insight on the potential role of amcenestrant in the treatment of HR+ breast cancer in the future.
AMEERA-5: Key Data and Implications for Practice
June 30, 2021
An expert in breast oncology shares her thoughts on the importance of the AMEERA-5 findings to the evolving treatment landscape for HR+ breast cancer.
Safety and Efficacy of Amcenestrant in the AMEERA Trials
June 30, 2021
Sara Hurvitz, MD, reviews clinical trial data on amcenestrant, an orally administered endocrine therapy, in patients with ER+/HER2- breast cancer as shown in the AMEERA trials.
Treatment Options For Advanced ER+ Breast Cancer
June 30, 2021
Sara Hurvitz, MD, discusses the therapeutic landscape for HR+ advanced breast cancer and considerations for treatment selection.
Understanding the Scope of ER+ Breast Cancer
June 30, 2021
Sara Hurvitz, MD, provides an overview of HR+ breast cancer.
Balixafortide and Eribulin Shows Modest Responses in Patients with HER2-Negative Breast Cancer
June 29, 2021
Balixafortide in combination with eribulin did not improve objective response rate compared to eribulin alone for the treatment of HER2-negative, locally recurrent or metastatic breast cancer, missing the coprimary end point of the FORTRESS study.